U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

DS Stage II Plasma Cell Myeloma

MedGen UID:
82968
•Concept ID:
C0278723
•
Neoplastic Process
Synonyms: DS Stage II Multiple Myeloma; Durie/Salmon Stage II Multiple Myeloma; Durie/Salmon Stage II Plasma Cell Myeloma; Multiple Myeloma Stage II; Stage II Multiple Myeloma; Stage II Plasma Cell Myeloma

Definition

Plasma cell myeloma that fits in neither stage I nor stage III. Estimated myeloma cell mass: 0.6 to 1.2 trillion (1012)/m2 (intermediate burden). The following subclassification of stages is used: a. Creatinine less than 2.0 mg/dL, b. Creatinine greater than or equal to 2.0 mg/dL. Impaired renal function worsens prognosis regardless of stage. Note that the newer International Staging System defines stage II quite differently: Beta-2-microglobulin less than 3.5 and albumin less than 3.5 or beta-2-microglobulin 3.5 to less than 5.5 (median survival of 44 months). (PDQ) [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVDS Stage II Plasma Cell Myeloma

Professional guidelines

PubMed

Diagnosis and treatment of multiple myeloma in Hunan Province.
Liu F, Cheng Q, Song K, Yu H, Li J, Zhang H, Hu G, Zhou M, Wang J, Ding Z, Luo Z, Peng T, Ding L, Zhao L, Liu J, He Y, Peng H
Zhong Nan Da Xue Xue Bao Yi Xue Ban 2022 Apr 28;47(4):497-504. doi: 10.11817/j.issn.1672-7347.2022.210555. PMID: 35545345

Recent clinical studies

Etiology

Diagnosis and treatment of multiple myeloma in Hunan Province.
Liu F, Cheng Q, Song K, Yu H, Li J, Zhang H, Hu G, Zhou M, Wang J, Ding Z, Luo Z, Peng T, Ding L, Zhao L, Liu J, He Y, Peng H
Zhong Nan Da Xue Xue Bao Yi Xue Ban 2022 Apr 28;47(4):497-504. doi: 10.11817/j.issn.1672-7347.2022.210555. PMID: 35545345
Association of Growth Differentiation Factor-15 Polymorphisms and Growth Differentiation Factor-15 Serum Levels with Susceptibility to Multiple Myeloma in a Chinese Population.
Li R, Hu Z, Chen H, Lu Y, Qin S, Huang C, Yao Y, Qin X, Wang C
Clin Lab 2021 Jan 1;67(1) doi: 10.7754/Clin.Lab.2020.200341. PMID: 33491432
Characterizing the Tumor Suppressor Role of CEACAM1 in Multiple Myeloma.
Xu J, Liu B, Ma S, Zhang J, Ji Y, Xu L, Zhu M, Chen S, Wu X, Wu D
Cell Physiol Biochem 2018;45(4):1631-1640. Epub 2018 Feb 21 doi: 10.1159/000487730. PMID: 29486474
The relationship between some soluble osteogenic markers, angiogenic cytokines/other biological parameters and the stages of multiple myeloma evaluated according to the Durie-Salmon and International Prognostic Index stratification systems.
Scudla V, Pika T, Budikova M, Petrova P, Bacovsky J, Srovnalik K, Minarik J, Langova K
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009 Dec;153(4):275-82. doi: 10.5507/bp.2009.046. PMID: 20208967
Multiple myeloma in elderly patients: presenting features and outcome.
Rodon P, Linassier C, Gauvain JB, Benboubker L, Goupille P, Maigre M, Luthier F, Dugay J, Lucas V, Colombat P
Eur J Haematol 2001 Jan;66(1):11-7. doi: 10.1034/j.1600-0609.2001.00301.x. PMID: 11168502

Diagnosis

Diagnosis and treatment of multiple myeloma in Hunan Province.
Liu F, Cheng Q, Song K, Yu H, Li J, Zhang H, Hu G, Zhou M, Wang J, Ding Z, Luo Z, Peng T, Ding L, Zhao L, Liu J, He Y, Peng H
Zhong Nan Da Xue Xue Bao Yi Xue Ban 2022 Apr 28;47(4):497-504. doi: 10.11817/j.issn.1672-7347.2022.210555. PMID: 35545345
Association of Growth Differentiation Factor-15 Polymorphisms and Growth Differentiation Factor-15 Serum Levels with Susceptibility to Multiple Myeloma in a Chinese Population.
Li R, Hu Z, Chen H, Lu Y, Qin S, Huang C, Yao Y, Qin X, Wang C
Clin Lab 2021 Jan 1;67(1) doi: 10.7754/Clin.Lab.2020.200341. PMID: 33491432
The Role of (18)F-FDG PET/CT in Multiple Myeloma Staging according to IMPeTUs: Comparison of the Durie-Salmon Plus and Other Staging Systems.
Deng S, Zhang B, Zhou Y, Xu X, Li J, Sang S, Zhang W
Contrast Media Mol Imaging 2018;2018:4198673. Epub 2018 Jul 30 doi: 10.1155/2018/4198673. PMID: 30154686Free PMC Article
Characterizing the Tumor Suppressor Role of CEACAM1 in Multiple Myeloma.
Xu J, Liu B, Ma S, Zhang J, Ji Y, Xu L, Zhu M, Chen S, Wu X, Wu D
Cell Physiol Biochem 2018;45(4):1631-1640. Epub 2018 Feb 21 doi: 10.1159/000487730. PMID: 29486474
Multiple myeloma in elderly patients: presenting features and outcome.
Rodon P, Linassier C, Gauvain JB, Benboubker L, Goupille P, Maigre M, Luthier F, Dugay J, Lucas V, Colombat P
Eur J Haematol 2001 Jan;66(1):11-7. doi: 10.1034/j.1600-0609.2001.00301.x. PMID: 11168502

Therapy

Diagnosis and treatment of multiple myeloma in Hunan Province.
Liu F, Cheng Q, Song K, Yu H, Li J, Zhang H, Hu G, Zhou M, Wang J, Ding Z, Luo Z, Peng T, Ding L, Zhao L, Liu J, He Y, Peng H
Zhong Nan Da Xue Xue Bao Yi Xue Ban 2022 Apr 28;47(4):497-504. doi: 10.11817/j.issn.1672-7347.2022.210555. PMID: 35545345
Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Rodriguez TE, Hari P, Stiff PJ, Smith SE, Sterrenberg D, Vesole DH
Biol Blood Marrow Transplant 2016 Aug;22(8):1391-1396. Epub 2016 May 7 doi: 10.1016/j.bbmt.2016.03.021. PMID: 27164062Free PMC Article
International Staging System predicts prognosis of Chinese patients with multiple myeloma across different calendar periods with application of novel agents.
Yang SH, Teng HW, Hong YC, Liu CY, Yu YB, Yang CF, Gau JP, Liu JH, Chang TJ, Yen JJ, Chen PM, Chiou TJ, Tzeng CH, Hsiao LT
Ann Hematol 2012 Jan;91(1):93-102. Epub 2011 May 17 doi: 10.1007/s00277-011-1251-y. PMID: 21584671
Multiple myeloma in elderly patients: presenting features and outcome.
Rodon P, Linassier C, Gauvain JB, Benboubker L, Goupille P, Maigre M, Luthier F, Dugay J, Lucas V, Colombat P
Eur J Haematol 2001 Jan;66(1):11-7. doi: 10.1034/j.1600-0609.2001.00301.x. PMID: 11168502

Prognosis

Diagnosis and treatment of multiple myeloma in Hunan Province.
Liu F, Cheng Q, Song K, Yu H, Li J, Zhang H, Hu G, Zhou M, Wang J, Ding Z, Luo Z, Peng T, Ding L, Zhao L, Liu J, He Y, Peng H
Zhong Nan Da Xue Xue Bao Yi Xue Ban 2022 Apr 28;47(4):497-504. doi: 10.11817/j.issn.1672-7347.2022.210555. PMID: 35545345
The Role of (18)F-FDG PET/CT in Multiple Myeloma Staging according to IMPeTUs: Comparison of the Durie-Salmon Plus and Other Staging Systems.
Deng S, Zhang B, Zhou Y, Xu X, Li J, Sang S, Zhang W
Contrast Media Mol Imaging 2018;2018:4198673. Epub 2018 Jul 30 doi: 10.1155/2018/4198673. PMID: 30154686Free PMC Article
International Staging System predicts prognosis of Chinese patients with multiple myeloma across different calendar periods with application of novel agents.
Yang SH, Teng HW, Hong YC, Liu CY, Yu YB, Yang CF, Gau JP, Liu JH, Chang TJ, Yen JJ, Chen PM, Chiou TJ, Tzeng CH, Hsiao LT
Ann Hematol 2012 Jan;91(1):93-102. Epub 2011 May 17 doi: 10.1007/s00277-011-1251-y. PMID: 21584671
The relationship between some soluble osteogenic markers, angiogenic cytokines/other biological parameters and the stages of multiple myeloma evaluated according to the Durie-Salmon and International Prognostic Index stratification systems.
Scudla V, Pika T, Budikova M, Petrova P, Bacovsky J, Srovnalik K, Minarik J, Langova K
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009 Dec;153(4):275-82. doi: 10.5507/bp.2009.046. PMID: 20208967
Multiple myeloma in elderly patients: presenting features and outcome.
Rodon P, Linassier C, Gauvain JB, Benboubker L, Goupille P, Maigre M, Luthier F, Dugay J, Lucas V, Colombat P
Eur J Haematol 2001 Jan;66(1):11-7. doi: 10.1034/j.1600-0609.2001.00301.x. PMID: 11168502

Clinical prediction guides

The Role of (18)F-FDG PET/CT in Multiple Myeloma Staging according to IMPeTUs: Comparison of the Durie-Salmon Plus and Other Staging Systems.
Deng S, Zhang B, Zhou Y, Xu X, Li J, Sang S, Zhang W
Contrast Media Mol Imaging 2018;2018:4198673. Epub 2018 Jul 30 doi: 10.1155/2018/4198673. PMID: 30154686Free PMC Article
Predictive value of (18) F-FDG PET/CT scanning in combination with clinical parameters in patients with newly diagnosed multiple myeloma.
Tu H, He Y, Huang T, Choe S, Lan X, Duan X, Sattar H, Li C, Zhou F
Eur J Haematol 2018 Feb;100(2):189-197. Epub 2017 Dec 29 doi: 10.1111/ejh.13006. PMID: 29226428
Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Rodriguez TE, Hari P, Stiff PJ, Smith SE, Sterrenberg D, Vesole DH
Biol Blood Marrow Transplant 2016 Aug;22(8):1391-1396. Epub 2016 May 7 doi: 10.1016/j.bbmt.2016.03.021. PMID: 27164062Free PMC Article
Absence of methylation-dependent transcriptional silencing in TP73 irrespective of the methylation status of the CDKN2A CpG island in plasma cell neoplasia.
Hatzimichael E, Benetatos L, Dasoula A, Dranitsaris G, Tsiara S, Georgiou I, Syrrou M, Stebbing J, Coley HM, Crook T, Bourantas KL
Leuk Res 2009 Sep;33(9):1272-5. Epub 2009 May 6 doi: 10.1016/j.leukres.2009.04.009. PMID: 19423161
Multiple myeloma in elderly patients: presenting features and outcome.
Rodon P, Linassier C, Gauvain JB, Benboubker L, Goupille P, Maigre M, Luthier F, Dugay J, Lucas V, Colombat P
Eur J Haematol 2001 Jan;66(1):11-7. doi: 10.1034/j.1600-0609.2001.00301.x. PMID: 11168502

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...